See more : Charter Hall Retail REIT (CQR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Strainsforpains, Inc. (EBYH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Strainsforpains, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- RiverNorth Flexible Municipal Income Fund, Inc. (RFM) Income Statement Analysis – Financial Results
- Welbe, Inc. (6556.T) Income Statement Analysis – Financial Results
- North American Exploration Corp. (NAMX) Income Statement Analysis – Financial Results
- Littelfuse, Inc. (LFUS) Income Statement Analysis – Financial Results
- Ocado Group plc (OCDDY) Income Statement Analysis – Financial Results
Strainsforpains, Inc. (EBYH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://strainsforpains.com
About Strainsforpains, Inc.
Strainsforpains, Inc. operates as a medical marijuana data recommendation system. The company develops Strainsforpains app, a user-based application that scientifically determines which cannabis brand or strain is right for patients based upon personal data and strain genetics. It serves medical specialists, dispensaries, and consumers. The company was incorporated in 1990 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84.12K | 7.39K | 9.11K | 21.56K | 9.45K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.38K | 168.00 | 0.00 | 0.00 | 10.00K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 84.12K | 7.39K | 9.11K | 21.56K | 9.45K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.38K | 168.00 | 0.00 | 0.00 | 10.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 50.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 448.05K | 0.00 | 24.82K | 12.48K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.58K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 149.72K | 112.80K | 139.17K | 84.33K | 97.54K | 58.01K | 66.08K | 486.45K | 2.03K | 18.16K | 0.00 | 560.07K | 654.10K | 840.46K | 439.66K | 451.63K | 890.34K | 24.82K | 12.48K | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 149.72K | 112.80K | 139.17K | 84.33K | 97.54K | 58.01K | 66.08K | 486.45K | 2.03K | 18.16K | 0.00 | 562.07K | 699.68K | 979.53K | 526.83K | 515.80K | 2.28M | 516.72K | 13.24M | 1.58K |
| Cost & Expenses | 149.72K | 112.80K | 139.17K | 84.33K | 97.54K | 58.01K | 66.08K | 486.45K | 2.03K | 18.16K | 0.00 | 562.07K | 699.68K | 979.53K | 526.83K | 515.80K | 2.28M | 516.72K | 13.24M | 1.58K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 84.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 116.58K | 116.58K | 116.58K | 0.00 | 1.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 84.64K | 0.00 | 73.86K | 34.56K | 22.35K | 21.75K | 15.25K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 0.00 | 0.00 | 0.00 | 0.00 | 18.16 | 0.00 | 2.00K | 45.58K | 88.16K | 87.17K | 64.17K | 116.17K | 170.59K | -26.44M | -3.15K |
| EBITDA | -65.61K | -105.41K | -130.07K | -62.77K | -88.09K | -56.01K | -66.08K | -486.45K | -2.03K | -18.16K | 0.00 | -581.03K | -711.04K | -889.99K | -439.49K | -451.63K | -890.34K | -336.14K | -13.20M | -1.58K |
| EBITDA Ratio | -78.00% | -1,425.90% | -1,428.29% | -291.14% | -932.17% | -2,800.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -66,431.38% | -261,602.98% | 0.00% | 0.00% | -2,685.18% | 0.00% | 0.00% |
| Operating Income | -65.61K | -105.41K | -130.07K | -62.77K | -88.09K | -56.01K | -66.08K | -486.45K | -2.02K | -18.16K | 0.00 | 562.07K | 699.68K | 978.14K | 526.66K | 515.80K | 2.28M | 506.72K | 13.24M | 1.58K |
| Operating Income Ratio | -78.00% | -1,425.90% | -1,428.29% | -291.14% | -932.17% | -2,800.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 70,726.25% | 313,489.29% | 0.00% | 0.00% | 5,067.20% | 0.00% | 0.00% |
| Total Other Income/Expenses | -116.58K | -116.58K | -116.58K | -90.53K | -238.25K | -2.00K | 4.00 | -4.00 | -5.00 | -84.64K | -84.64K | -20.95K | -73.86K | -5.80K | -22.35K | -1.05M | -1.28M | -67.62K | -26.51M | -3.15K |
| Income Before Tax | -182.19K | -221.99K | -246.65K | -153.30K | -326.34K | -58.01K | -66.08K | -486.45K | -2.03K | -102.80K | -84.64K | -583.02K | -773.54K | -983.94K | -549.01K | -537.55K | 1.01M | -574.34K | -13.28M | -1.58K |
| Income Before Tax Ratio | -216.59% | -3,002.82% | -2,708.43% | -711.04% | -3,453.31% | -2,900.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -71,145.48% | -326,791.07% | 0.00% | 0.00% | -5,743.37% | 0.00% | 0.00% |
| Income Tax Expense | -167.90K | -228.49K | -236.56K | -206.30K | -171.86K | 0.00 | 0.00 | 0.00 | 0.00 | -18.16 | 0.00 | 20.95K | -1.40M | 5.80K | -1.05M | -1.03M | 15.25K | 67.62K | 26.48M | 0.00 |
| Net Income | -182.19K | -221.99K | -246.65K | -153.30K | -326.34K | -58.01K | -66.08K | -486.45K | -2.03K | -102.80K | -84.64K | -583.02K | -773.54K | -983.94K | -549.01K | -537.55K | -2.30M | -574.34K | -13.28M | -1.58K |
| Net Income Ratio | -216.59% | -3,002.82% | -2,708.43% | -711.04% | -3,453.31% | -2,900.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -71,145.48% | -326,791.07% | 0.00% | 0.00% | -5,743.37% | 0.00% | 0.00% |
| EPS | -0.01 | -0.02 | -0.02 | -0.01 | -0.03 | -0.01 | -0.01 | -0.05 | 0.00 | -0.23 | -0.19 | -1.86 | -2.47 | -7.44 | -4.31 | -7.10 | -81.69 | -39.55 | -1.17K | -0.23 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.01 | -0.03 | -0.01 | -0.01 | -0.05 | 0.00 | -0.23 | -0.19 | -1.86 | -2.47 | -7.44 | -4.31 | -7.10 | -81.69 | -39.55 | -1.17K | -0.23 |
| Weighted Avg Shares Out | 13.89M | 12.84M | 12.09M | 11.61M | 11.61M | 10.51M | 10.45M | 10.45M | 447.36K | 447.36K | 447.36K | 313.00K | 313.00K | 132.30K | 127.40K | 75.76K | 28.11K | 14.52K | 11.30K | 6.71K |
| Weighted Avg Shares Out (Dil) | 13.89M | 12.84M | 12.09M | 11.61M | 11.61M | 10.51M | 10.45M | 10.45M | 447.36K | 447.36K | 447.36K | 313.00K | 313.00K | 132.30K | 127.40K | 75.76K | 28.11K | 14.52K | 11.30K | 6.71K |
Strainsforpains EBYH (OTC: EBYH), Collaborates with Mt. Sinai Hospital in New York City and Johns Hopkins in Baltimore to Merge Advanced AI Data Integrations and Interactions Into Its Proprietary Healthcare APP for Instant Multiple Indications and Critical Ailments Professional Analytics
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. fka/ E-Buy Home, Inc. (OTC: EBYH), a leader in the health and wellness sector for 17 years, is proud to announce its collaboration with renowned Institutions Mt. Sinai in New...
Strainsforpains (OTC: EBYH) Formally Announces Alliance with the 1-Million Strong Killing Cancers, Fight Club (1MSFC) and the Inaugural Live 1MSFC #1 MMA Fight for 4th Quarter 2024 in Florida! Appoints Former WWE, TV Executive VP, Mr.
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Strainsforpains, Inc., fka/ E-Buy Home Inc., (OTC: EBYH) an emerging cannabinoid-based retail and wholesale drug commercialization specialist is very pleased to announce its alliance with the 1-Million Strong Killing Cancers, Fight Club...
Strainsforpains-EBYH, CEO Simon Shainberg Signs Strategic Product Commercialization Agreement with Cannabis Science; Shainberg's 2024 Guidance Projects Strong Revenue Growth For Its Multiplied Cannabinoid Drug Commercialization Pipeline
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Strainsforpains, Inc., fka/ E-Buy Home Inc., (OTC: EBYH) an emerging cannabinoid-based retail and wholesale drug commercialization specialist is very pleased to announce that it has just signed an international retail and wholesale...
Strainsforpains, Inc. Investors Update: Strainsforpains, Inc. Showing Strong Revenue Growth
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- -- (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH) Strainsforpains, Inc. is pleased to announce the successful acquisition of a substantial $130,000 distribution order from Exploration Solutions, LLC, (ESLLC) a Brooklyn, NY...
StrainsForPains, Inc. Discusses Inspiration, App Technology and CBD Market Entrance with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - February 29, 2024) - The Stock Day Podcast welcomed StrainsForPains, Inc. (OTC Pink: EBYH) ("the Company"), a medical marijuana recommendation engine that guides patients to the appropriate cannabinoid levels, medical cannabis strains, and consumption methods for...
Strainsforpains Inc. Announces Corporate Update
NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- (Strainsforpains, Inc.) (OTC Markets: EBYH). Strainsforpains is pleased to announce that it has increased the capacity of its Pennsylvania facility to accommodate the company's growing CBD product line.
Strainsforpains, Inc. secures its largest orders to date from NYC establishments
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. Announces Corporate Update (Strainsforpains, Inc.) (OTC Markets: EBYH). Strainsforpains, Inc. is pleased to announce it has closed out 2023 with its largest orders to date, valued at $65,000, from various...
Source: https://incomestatements.info
Category: Stock Reports